1. Xác định hiệu quả phối hợp hai carbapenem in vitro trên các chủng K. Pneumoniae sinh carbapenemase
Nội dung chính của bài viết
Tóm tắt
Thử nghiệm đánh giá hiệu quả phối hợp hai carbapenem bằng Etest trên 50 chủng K. pneumoniae đề kháng carbapenem ở các mức độ khác nhau được cho thấy cặp phối hợp ertapenem + meropenem có hiệu quả hiệp đồng tác dụng trên 3 chủng, cộng tác dụng trên 47 chủng còn cặp cặp phối hợp ertapenem + imipenem có hiệu quả hiệp đồng tác dụng trên 7 chủng, cộng tác dụng trên 43 chủng. Không có hiện tượng đối kháng tác dụng khi phối hợp các cặp kháng sinh khác nhau trên cả 50 chủng. Khả năng hiệp đồng tác dụng của phối hợp ertapenem + imipenem có xu hướng tăng lên khi MIC carbapenem thấp. Phối hợp hai carbapenem là một lựa chọn điều trị có thể cân nhắc cho các nhiễm trùng K. pneumoniae kháng carbapenem.
Chi tiết bài viết
Từ khóa
K. pneumoniae, phối hợp hai carbapenem
Tài liệu tham khảo
1. WHO. Antimicrobial resistance. Accessed June 8, 2019. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.
2. WHO. Ten health issues WHO will tackle this year. Accessed June 9, 2019. https://www.who.int/emergencies/ten-threats-to-global-health-in-2019.
3. WHO. WHO publishes list of bacteria for which new antibiotics are urgently needed. Accessed June 8, 2019. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.
4. Trecarichi EM, Tumbarello M. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence. 2017;8(4):470-484.
5. Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections caused by xarbapenem-resistant Enterobacteriaceae: An update on therapeutic options. Front Microbiol. 2019;10:80.
6. Souli M, Karaiskos I, Masgala A, Galani L, Barmpouti E, Giamarellou H. Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2017;36(7):1305-1315.
7. De Pascale G, Martucci G, Montini L, et al. Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: A two-center, matched case-control study. Crit Care. 2017;21(1):173.
8. Oliva A, Gizzi F, Mascellino MT, et al. Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2016;22(2):147-153.
9. Cprek JB, Gallagher JC. Ertapenem-containing double-carbapenem therapy for treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015;60(1):669-673.
10. Cancelli F, Oliva A, De Angelis M, Mascellino MT, Mastroianni CM, Vullo V. Role of double-carbapenem regimen in the treatment of infections due to carbapenemase producing carbapenem-resistant Enterobacteriaceae: A single-center, observational study. BioMed Res Int. 2018. doi: 10.1155/2018/2785696.
11. Mashni O, Nazer L, Le J. Critical review of double-carbapenem therapy for the treatment of carbapenemase-producing Klebsiella pneumoniae. Ann Pharmacother. 2019;53(1):70-81.
12. Poirel L, Kieffer N, Nordmann P. In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2016;71(1):156-161.
13. Oliva A, Scorzolini L, Cipolla A, et al. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: The activity of the double-carbapenem regimen is related to meropenem MIC value. J Antimicrob Chemother. 2017;72(7):1981-1984.
14. Galani I, Nafplioti K, Chatzikonstantinou M, Souli M. In vitro evaluation of double-carbapenem combinations against OXA-48-producing Klebsiella pneumoniae isolates using time-kill studies. J Med Microbiol. Published online March 21, 2018. doi: 10.1099/jmm.0.000725.
15. Hsu L-Y, Apisarnthanarak A, Khan E, Suwantarat N, Ghafur A, Tambyah PA. Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clin Microbiol Rev. 2017;30(1):1-22.
16. Phạm Hồng Nhung, Đào Xuân Cơ, Bùi Thị Hảo. Mức độ nhạy cảm với kháng sinh của các trực khuẩn Gram âm phân lập tại Khoa Điều trị tích cực Bệnh viện Bạch Mai. Tạp chí nghiên cứu Y học. 2017;109(4).
17. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (When) Might we still consider treating with carbapenems?. Clin Microbiol Infect. 2011;17(8):1135-1141.
18. Couffignal C, Pajot O, Laouenan C, et al. Population pharmacokinetics of imipenem in critically ill patients with suspected ventilation-associated pneumonia and evaluation dosage regimens. Br J Clin Pharmacol. 2014;78(5):1022-1034.
19. Walther-Rasmussen J, Hoiby N. Class A carbapenemases. J Antimicrob Chemother. 2007;60(3):470-482.
20. Docquier J-D, Calderone V, De Luca F, et al. Crystal structure of the OXA-48 β-Lactamase reveals mechanistic diversity among class D carbapenemases. Chem Biol. 2009;16(5):540-547.
2. WHO. Ten health issues WHO will tackle this year. Accessed June 9, 2019. https://www.who.int/emergencies/ten-threats-to-global-health-in-2019.
3. WHO. WHO publishes list of bacteria for which new antibiotics are urgently needed. Accessed June 8, 2019. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.
4. Trecarichi EM, Tumbarello M. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence. 2017;8(4):470-484.
5. Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections caused by xarbapenem-resistant Enterobacteriaceae: An update on therapeutic options. Front Microbiol. 2019;10:80.
6. Souli M, Karaiskos I, Masgala A, Galani L, Barmpouti E, Giamarellou H. Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2017;36(7):1305-1315.
7. De Pascale G, Martucci G, Montini L, et al. Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: A two-center, matched case-control study. Crit Care. 2017;21(1):173.
8. Oliva A, Gizzi F, Mascellino MT, et al. Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2016;22(2):147-153.
9. Cprek JB, Gallagher JC. Ertapenem-containing double-carbapenem therapy for treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015;60(1):669-673.
10. Cancelli F, Oliva A, De Angelis M, Mascellino MT, Mastroianni CM, Vullo V. Role of double-carbapenem regimen in the treatment of infections due to carbapenemase producing carbapenem-resistant Enterobacteriaceae: A single-center, observational study. BioMed Res Int. 2018. doi: 10.1155/2018/2785696.
11. Mashni O, Nazer L, Le J. Critical review of double-carbapenem therapy for the treatment of carbapenemase-producing Klebsiella pneumoniae. Ann Pharmacother. 2019;53(1):70-81.
12. Poirel L, Kieffer N, Nordmann P. In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2016;71(1):156-161.
13. Oliva A, Scorzolini L, Cipolla A, et al. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: The activity of the double-carbapenem regimen is related to meropenem MIC value. J Antimicrob Chemother. 2017;72(7):1981-1984.
14. Galani I, Nafplioti K, Chatzikonstantinou M, Souli M. In vitro evaluation of double-carbapenem combinations against OXA-48-producing Klebsiella pneumoniae isolates using time-kill studies. J Med Microbiol. Published online March 21, 2018. doi: 10.1099/jmm.0.000725.
15. Hsu L-Y, Apisarnthanarak A, Khan E, Suwantarat N, Ghafur A, Tambyah PA. Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clin Microbiol Rev. 2017;30(1):1-22.
16. Phạm Hồng Nhung, Đào Xuân Cơ, Bùi Thị Hảo. Mức độ nhạy cảm với kháng sinh của các trực khuẩn Gram âm phân lập tại Khoa Điều trị tích cực Bệnh viện Bạch Mai. Tạp chí nghiên cứu Y học. 2017;109(4).
17. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (When) Might we still consider treating with carbapenems?. Clin Microbiol Infect. 2011;17(8):1135-1141.
18. Couffignal C, Pajot O, Laouenan C, et al. Population pharmacokinetics of imipenem in critically ill patients with suspected ventilation-associated pneumonia and evaluation dosage regimens. Br J Clin Pharmacol. 2014;78(5):1022-1034.
19. Walther-Rasmussen J, Hoiby N. Class A carbapenemases. J Antimicrob Chemother. 2007;60(3):470-482.
20. Docquier J-D, Calderone V, De Luca F, et al. Crystal structure of the OXA-48 β-Lactamase reveals mechanistic diversity among class D carbapenemases. Chem Biol. 2009;16(5):540-547.